The novel therapy of the medication represents a significant development in the care of type 2 diabetes. Unlike existing therapies, tirzepatide affects two pathways – glucagon-like peptide-1 (GLP-1) and the GIP https://tirzepatide-peptide646263.blogdemls.com/41819504/tirzepatide-peptide-a-new-frontier-in-diabetes-treatment